Stryker completes sale of U.S. spinal implants business

Rhea-AI Summary

Stryker (NYSE: SYK) has completed the sale of its U.S. spinal implants business to Viscogliosi Brothers, , which will operate under the newly formed VB Spine, . The strategic divestment aims to enhance Stryker's focus and enable investments in areas with greater innovation and growth potential.

As part of the agreement, VB Spine will have exclusive access to Mako Spine and Copilot technologies for spine procedures. Stryker maintains its presence in the spine sector through its Interventional Spine, Neurotechnology, and Enabling Technologies businesses, along with a strategic partnership with VB Spine.

The transaction's international component will be executed in phases, with transfers to VB Spine in certain markets pending legal, regulatory, and employee consultation requirements.

Positive

• Strategic divestment allows focus on higher-growth opportunities
• Maintains revenue potential through strategic partnership with VB Spine
• Retains presence in spine market through other business segments

Negative

• Loss of direct revenue from U.S. spinal implants business
• Delayed international market transitions may impact overall deal completion timeline

Portage, Michigan, April 01, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE: SYK), a global leader in medical technologies, announced today that it has completed the sale of its U.S. spinal implants business to Viscogliosi Brothers, LLC, as part of the newly formed company VB Spine, LLC.

“The sale of our spinal implants business enhances our strategic focus, positioning us to meet evolving customer needs and invest where we see the greatest opportunity for innovation and long-term growth,” said Kevin Lobo, Chair and CEO, Stryker. “We remain committed to the spine space through our Interventional Spine, Neurotechnology and Enabling Technologies businesses, as well as our strategic partnership with VB Spine. We’re grateful to our Spine team members for their contributions and confident they’re well positioned for continued success.”

VB Spine will have exclusive access to Mako Spine and Copilot for use with its implants in spine procedures.

Certain international markets are expected to transfer to VB Spine at later dates, subject to the completion of all legal and regulatory requirements and required consultations with employees and/or employee representatives.

About Stryker

Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. More information is available at www.stryker.com.

Contacts

For investor inquiries:
Jason Beach, Vice President, Finance and Investor Relations at 269-385-2600 or jason.beach@stryker.com

For media inquiries:
Kim Montagnino, Chief Communications Officer at 269-385-2600 or kim.montagnino@stryker.com 

FAQ

What assets did Stryker (SYK) sell to VB Spine in April 2025?

Stryker sold its U.S. spinal implants business to VB Spine, , a newly formed company by Viscogliosi Brothers,

Will Stryker (SYK) completely exit the spine market after this sale?

No, Stryker remains in the spine space through Interventional Spine, Neurotechnology, Enabling Technologies, and a strategic partnership with VB Spine.

What technology access does VB Spine receive in the Stryker (SYK) deal?

VB Spine receives exclusive access to Mako Spine and Copilot technologies for use with its implants in spine procedures.

How will the international markets transition in the Stryker (SYK) spine business sale?

International markets will transfer to VB Spine at later dates, subject to legal, regulatory requirements, and employee consultations.